How GDP, GWP and GCP Apply to Clinical Trial Supply in Australia
Clinical trial supply in Australia operates across several regulatory and quality frameworks. Sponsors must understand how Good Distribution Practice, Good Wholesaling Practice and Good Clinical Practice work together to protect investigational product and maintain clear accountability throughout the supply chain. Weaknesses in storage, transport, documentation or handover controls can delay supply, increase product loss and require formal investigation.
The Australian Regulatory Framework
Australia does not operate a standalone national GDP certification scheme equivalent to the European model.
Medicine wholesaling is regulated through state and territory legislation, licensing requirements and the Australian Code of Good Wholesaling Practice. Clinical trial supply is also governed by Good Clinical Practice, the approved protocol and relevant TGA requirements.
Where an unapproved therapeutic good is supplied for an Australian clinical trial, Human Research Ethics Committee approval and the applicable Clinical Trial Notification or Clinical Trial Approval requirements must be in place. Import, biosecurity or controlled drug permits may also apply.
GDP aligned controls support product quality, security, traceability and accountability throughout the clinical supply chain.
Where Clinical Supply Risks Arise
Risk often occurs where responsibility passes between organisations, including manufacturer to importer, importer to depot, depot to carrier and carrier to clinical site.
Packaging performance, delays, temporary storage conditions and the timely review of temperature data can all affect product integrity. A temperature excursion does not automatically mean a medicine is unsuitable for use, but it does require quarantine, investigation and documented assessment.
Schedule 8 and Schedule 9 medicines require additional security and inventory controls. Refrigerated Schedule 8 medicines must maintain secure controlled drug storage and validated cold chain conditions at the same time.
What Sponsors Should Look For
Sponsors should review temperature mapping and monitoring, deviation and corrective action processes, staff training, carrier qualification, stock reconciliation, access controls and chain of custody documentation.
Quality agreements should also define responsibilities for quarantine, dispatch, temperature excursions, returns, recalls and destruction.
How HL Pharma Supports Compliant Clinical Supply
HL Pharma provides clinical trial storage and distribution from our purpose built pharmaceutical facility in Melbourne. Our operations are managed through an ISO 9001:2015 certified quality system aligned with Australian GWP and internationally recognised GDP principles.
We provide validated controlled room temperature, refrigerated and frozen storage to minus 20 degrees Celsius, together with secure Schedule 8 and Schedule 9 storage. This includes refrigerated Schedule 8 medicines between plus 2 and plus 8 degrees Celsius within secure, continuously monitored conditions.
Our team includes registered pharmacists and dedicated quality personnel experienced in clinical trial supply, regulated medicines and controlled drugs. We also hold relevant biosecurity import permits for biological products and support Early Access Programs and post clinical trial supply.
• Post-trial supply management: importation, storage, distribution and pharmacy dispensing for extension studies and continued access
• Permit support: biological import permits, controlled drug licences and regulatory paperwork
• TGA pathway advice: SAS, Authorised Prescriber and post-trial access routes
• Reverse logistics: return, reconciliation and destruction of unused trial materials
• Post-trial drug retention: secure, temperature-controlled storage after study completion
• Global medicine sourcing across Europe, the UK, India, the USA and beyond
• Temperature-controlled storage across CRT, refrigerated, frozen and ultra-low environments
• Schedule 8 and 9 vault storage with full ODC compliance
• Pharmacovigilance and TGA reporting support throughout the programme lifecycle
Talk to HL Pharma about GDP aligned clinical trial storage and distribution in Australia. Contact us at hlpharma.com.au/contact/ or call +61 3 7036 0141.
This article is directed at pharmacists, prescribers, hospital procurement teams and accredited healthcare facilities. It does not constitute advice to individual patients or consumers.